<DOC>
	<DOCNO>NCT00943748</DOCNO>
	<brief_summary>Few available drug slow progression neurodegenerative pathology Parkinson 's disease ( PD ) . One recent hypotheses concern reduction oxidative stress neuron death feature harmful effect iron , may reach abnormally high level substantia nigra ( SN ) par compacta ( iron overload see substantia nigra parkinsonian patient 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ( MPTP ) mouse model PD ) . Iron overload harmful reacts hydrogen peroxide ( H2O2 ) produce oxidative deamination dopamine , generate hydroxyl radical damage protein , DNA phospholipid membrane may responsible neuron death . The use iron chelator ( clioquinol ) produce reduction neuron death MPTP mouse model . In human , special , partially refocus interleaved multiple echo ( PRIME ) MR sequence use study relaxation time ( T2* ) quantify iron overload SN PD patient nucleus dentatus patient Friedreich 's ataxia . T2* sequence reveal decrease iron overload follow treatment chelator deferiprone , parallel clinical improvement patient . Furthermore , recent open label use deferiprone rare serious , systemic , neurological iron overload disease ( Neurodegeneration Brain Iron Accumulation ( NBIA ) ) reveal clinical improvement 6 month , 2 case report group another Italian group ( Forni et al. , 2008 ) . The safety low dosage deferiprone ( 20 30 mg/kg/day ) use neurology appear much great high dosage ( 75 100 mg/kg/day 3 dos ) use hematology decrease post-transfusion iron overload thalassemia major . Hence , investigator wish evaluate effect treatment oral iron chelator capable cross blood-brain barrier ( deferiprone ) iron overload SN ( assess T2* sequence ) respect progression clinical sign PD . It expect 6-month course deferiprone able produce moderate reduction iron overload SN , associate drop motor handicap score . Depending risk/benefit balance determine initial pilot study , large , multicenter neuroprotection study could envisage .</brief_summary>
	<brief_title>Efficacy Safety Iron Chelator Deferiprone Parkinson 's Disease</brief_title>
	<detailed_description>Primary objective : decrease iron overload ( measure T2* MRI sequence ) substantia nigra patient Parkinson 's disease ( PD ) 6 month deferiprone treatment , relative placebo group . Secondary objective : 1 . Other radiological criterion : Modification T2* MRI caudal nucleus head , putamen pallidum . 2 . Evaluate `` disease modifier '' effect clinical symptom : - Parkinsonian syndrome : UPDRS III - Clinical Global Impression score examiner patient . 3 . Evaluate safety cognitive behavioral function - MDS-UPDRS I - overall cognitive function ( Mattis , MMSE ) , memory , executive function , attention ( simple choice reaction time ) - drowsiness sleep ( Epworth scale , Parkinson Disease Sleep Scale ) , depression ( MADRS ) . 4 . Safety : complete blood count ( CBC ) weekly leukocyte count , standard blood biochemistry profile , blood iron profile , ECG , blood pressure , bodyweight , adverse event reporting . 5 . Specific biochemistry screen : heavy metal profile , oxidative stress dopamine metabolism . Study center : Service de Neurologie et Pathologie du Mouvement ( Head : Prof. Destée , Clinique Neurologique Service de Neuroradiologie ( Head : Prof. Pruvo ) , Salengro Hospital , Lille University Medical Center , Lille , France . Study characteristic : randomize , double-blind , placebo-controlled , parallel-group , single-center trial delay onset paradigm ( Early-start group 12 month deferiprone versus delayed -start group 6 month placebo 6 month deferiprone ) study effect deferiprone relaxation time substantia nigra T2* MRI sequence ( R2*=1/T2* reflect iron overload ) respect motor disorder Parkinson 's disease . Active compound : iron chelator 1,2-dimethyl-3-hydroxy-4-pyridinone ( deferiprone , FERRIPROX® ) , decrease abnormally high iron ferritin level . Its low molecular weight liposolubility enable cross blood-brain barrier . Posology : recommended dosage neurology total 30 mg/kg/day , 2 dos . Study population : 40 adult parkinsonian volunteer , early-stage PD first optimise dopaminergic therapeutic strategy ( i.e . either dopamine agonist and/or slight dose L-dopa ) free motor fluctuation dementia . Planned inclusion period : 12 month . Study duration individual patient : 13 month ( 2 week screen randomization , 6 month double-blind treatment , 6 month open label treatment 2-week wash-out period ) . Study procedures timeline : - A screening visit ( Sc ) . - Two comprehensive examination ( neurological neuropsychological check-up ) randomization visit ( V0 , D7-15 ± 1 week Sc ) , visit 6 month ( V6 , least 6 month V0 ) , visit 12 month ( V12 , least 12 month V0 ) - Weekly monitoring CBC leukocyte count , result fax patient 's local clinical lab Lille University Medical Center 's central lab . - Monitoring blood iron zinc status overall tolerance brief consultation : V1 , V3 , V5 , V7 , V9 , V11 - MRI external facility V0 , V6 , V12 . - Telephone follow-up : V2 , V4 , V8 , V10 - Patients invited participate ancillary study involve analysis cerebrospinal fluid ( CSF ) randomization visit V6 , order perform full set CSF biochemistry assay view determine biological benefit central nervous system level identify biological marker .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<mesh_term>Chelating Agents</mesh_term>
	<criteria>Patients typical Parkinson 's disease accord Gibb criterion Parkinson 's Disease Society criterion ( Daniel Lees , 1993 ) . Ideally less 2 3 year since disease onset never 4 year . Patients dopaminergic drug and/or LDopa . Nonfluctuating disease otherwise degenerative process would well advance , clinical score would vary one day another imaging evaluation would complicate dyskinesia . Subjects age 80 Demented subject : MMSE score ≤ 24 , Mattis score &lt; 130 DSM IV criterion Subjects radiological anomaly MRI , whether incidental suggestive vascular involvement significant cortical subcortical atrophy Subjects MRI contraindicate ( metal object body , severe claustrophobia , pacemaker , etc . ) Subjects undergoing brain stimulation Very severe rest tremor , could induce MRI artifact Subjects stabilize term therapeutic regimen likely require change dopamine therapy come 6 month Hoehn Yahr stage ≥ 3 `` Off '' state , indicate need walk assistance absence treatment . Hypersensitivity iron chelator drug Patients risk experience agranulocytosis Patients drug potentially induce agranulocytosis ( clozapine , Closaril®/Leponex® ) Patients anemia ( regardless latter 's etiology ) history hematological disease even iron deficiency Ferritin blood level &lt; 100 ng/ml ( 100 µg/l ) A history hemochromatosis know iron metabolism disorder . Pregnant breastfeed woman woman take effective contraception Kidney liver failure Blood coagulation disorder , antiplatelet drug anticoagulant Concomitant treatment aluminumbased antacid ( interaction ) Concomitant treatment vitamin C ( interaction ) Presence serious disease Inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>